Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20
Page views 365
Article views/downloads 3417
Get Citation

Connect on Social Media

Connect on Social Media

Diagnosis and treatment of patients with NSCLC EGFR Mut+

Ewa Skrzypczyńska

Abstract

Using tyrosine kinase inhibitors in the second line of treatment in patients with adenocarcinoma and EGFR activated mutation may slightly prolong the survival time. In patients with adenocarcinoma, with a positive mutation in the EGFR gene and progression after treatment of chemioterapy platinum-based — the drug of choice is erlotinib at a daily dose 150 mg. The case study present a few months survival without progression patient with diagnosis NSCLC EGFR Mut+ treated with erlotinib in the second line.

Article available in PDF format

Purchase Subscription